Clinical Trial: EFFECTIVENESS OF RITUXIMAB COMPARED WITH STANDARD THERAPY IN MODERATE TO SEVERE PEMPHIGUS VULGARIS

U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07769333) titled 'EFFECTIVENESS OF RITUXIMAB COMPARED WITH STANDARD THERAPY IN MODERATE TO SEVERE PEMPHIGUS VULGARIS' on Aug. 12.

Brief Summary: This quasi-experimental study aims to compare the effectiveness and safety of rituximab combined with corticosteroids versus the standard regimen of oral corticosteroids plus azathioprine in patients with moderate to severe pemphigus vulgaris.

Pemphigus vulgaris is a rare autoimmune blistering disease. Conventional treatment with high-dose corticosteroids and azathioprine, though effective, is associated with significant long-term side effects. Rituximab, a B-cell depleting monoclonal antibody, has emerged ...